Calif.-based Conor Medsystems hopes to enter the $5 billion stent market next year with CoStar, a stent that begins as a drug-eluting product and then ceases drug production and absorbs the polymer coating after six months, leaving a bare metal stent, which should minimize the problem of late-thrombosis that is an issue in other drug-eluting stents. Conor still faces obstacles, such as the need for more data, not-so-deep pockets, potential court battles and marketing competition.

Related Summaries